HPC DS - 2ml

Injection

Pack Size : 1 Injection x 1 Packet

Generics : Hydroxyprogesterone Caproate

Manufacturer : Popular Pharmaceuticals Ltd.

Best Price * TK 650.00

Refrigerated

* Delivery will be done in Dhaka city only.

Alternative Product

More Information About - HPC DS - 2ml

Description

Generic Name

Hydroxyprogesterone Caproate

Precaution

Physical examination is advised prior to starting therapy. Hepatic impairment, mental depression. Monitor blood glucose in diabetic patients. Discontinue treatment upon signs of thromboembolic and thrombotic disorders. Discontinue treatment if unexplained, sudden or gradual, partial or complete loss of vision, protopsis, diplopia or papilledema, retinal vascular lesions or migraine occur. Caution when used in patients with conditions that might be worsened by fluid retention (e.g. asthma, seizure disorders, migraine, cardiac or renal dysfunction).

Indication

Preterm Labor, Recurrent miscarriage, Amenorrhoea, Abnormal uterine bleeding, Palliative treatment of advanced, inoperable endometrial carcinoma

Contra Indication

Undiagnosed vaginal bleeding, breast cancer, pregnancy, lactation. Thrombophlebitis, thromboembolic disorders, cerebral apoplexy or a history of these conditions. Markedly impaired liver function.

Dose

N/A

Side Effect

N/A

Pregnancy Category

Name : Not Classified

Description

FDA has not yet classified the drug into a specified pregnancy category.

Mode of Action

Hydroxyprogesterone caproate stimulates luteal actions, changes in uterus and vagina as seen in early pregnancy. It also has prolonged uterotrophic effect. Contractile response of the myometrium to oxytocin is inhibited.

Interaction

Increased clearance when used with enzyme inducers e.g. carbamazepine and phenytoin. May inhibit metabolism of ciclosporin.

Pregnancy Category Note

Pregnancy Indicated to reduce the risk of preterm birth in women with a singleton pregnancy who have a history of singleton spontaneous preterm birth Data from the placebo-controlled clinical trial and the infant follow-up safety study did not show a difference in adverse developmental outcomes between children of progesterone caproate-treated women and children of control subjects However, these data are insufficient to determine a drug-associated risk of adverse developmental outcomes as none of the treated women received the drug during the first trimester of pregnancy Animal data In animal reproduction studies, IM administration to pregnant rats during gestation at doses 5 times the human dose equivalent based on a 60-kg human was not associated with adverse developmental outcomes Lactation Not indicated during time period when breastfeeding would occur Low levels of progestins are present in human milk with the use of progestin-containing products, including hydroxyprogesterone caproate Published studies have reported no adverse effects of progestins on the breastfed child or on milk production

Adult Dose

Intramuscular Preterm Labor Indicated for prevention of preterm labor in a singleton pregnancy for patients aged 16 years or older who have a history of spontaneous preterm birth 250 mg IM qWeek Initiate between the 16th and 20th week of gestation and ending at the 37th week of gestation or birth (whichever is first) Recurrent miscarriage Adult: 250-500 mg wkly during the 1st half of pregnancy. Amenorrhoea; Abnormal uterine bleeding Adult: Single dose of 375 mg; may repeat at 4-wkly intervals if needed. After 4 days of desquamation, or if there is no bleeding within 21 days after admin of the drug, may initiate cyclic therapy that includes an oestrogen. For cyclic treatment (28-day cycle): Administer 20 mg of estradiol valerate on day 1, and on day 15, administer 250 mg of hydroxyprogesterone caproate and 5 mg of estradiol valerate. May repeat cyclic therapy at 4-wkly intervals as needed. Palliative treatment of advanced, inoperable endometrial carcinoma Adult: Usual dose: >1 g, may repeat once or more times wkly. Usual range: 1-7 g/wk. Discontinue treatment if relapse occurs or if the objective response is not achieved after 12 wk of treatment. Hepatic Impairment Not studied; product is extensively metabolized in liver; potential for reduce elimination

Child Dose

Safety and efficacy not established

Renal Dose

Not studied in patients with renal impairment

Administration

IM Administration Inject IM over 1 minute in upper outer quadrant of the gluteus maximus Inject IM over 1 minute in upper outer quadrant of the gluteus maximus The solution if viscous and oilyThe solution if viscous and oily 1-mL vial does not contain preservatives and is for single dose use Once opened, the 5-mL multidose vial must be used within 5 weeks

Disclaimer

The information provided herein are for informational purposes only and not intended to be a substitute for professional medical advice, diagnosis, or treatment. Please note that this information should not be treated as a replacement for physical medical consultation or advice. Great effort has been placed to provide accurate and comprehensive data. However, Medicart along with its authors and editors make no representations or warranties and specifically disclaim all liability for any medical information provided on the site. The absence of any information and/or warning to any drug shall not be considered and assumed as an implied assurance of the Company.